[1]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844-847.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
 YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):844-847.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
点击复制

心源性外泌体作为冠心病标志物和新靶点展望()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年6期
页码:
844-847
栏目:
主题综述
出版日期:
2019-09-25

文章信息/Info

Title:
Exogenous Exosome as A New Marker and Target of Coronary Heart Disease
作者:
姚雯1毛露2孙硕1 Dirk Hermann 3陈艾东13
(南京医科大学心血管病靶向干预重点实验室,江苏 南京211166;2. 东南大学 东南医科大学附属中大医院,江苏 南京210096;3. 杜伊斯堡-埃森大学神经生物学研究中心,德国 埃森 45122 )
Author(s):
YAO Wen1 MAO Lu2 SUN Shuo1 DIRK Hermann3 CHEN Aidong13
(1. Key Laboratory of Targeting Interventions for Cardiovascular Diseases, Nanjing Medical University, Nanjing 211166, Jiangsu, China; 2. Zhongda Hospital Affiliated to Southeast University, Southeast Medical University, Nanjing 210096, Jiangsu, China; 3. Center for Neurobiology, Duisburg - Essen University, Essen 45122, Germany)
关键词:
外泌体冠心病生物标志物
Keywords:
Exosomes Coronary heart disease Biomarker
DOI:
10.16806/j.cnki.issn.1004-3934.2019.06.002
摘要:
心源性外泌体是由心脏细胞产生的包含大量生物活性分子的细胞外囊泡,他们是心脏细胞通讯的重要手段。冠心病时,心肌缺血缺氧损伤后,4 h 就可以产生一些特殊的心源性外泌体组分,可以作为早诊断的新标志物。心脏源性祖细胞等干细胞分泌的心源性外泌体,可以减少冠心病后心肌细胞凋亡、增加细胞管形成、减少纤维化的发展和改善心脏功能。这些心源性外泌体,可以装载对本病有治疗作用的药物,标记心肌靶向肽,发挥对缺血心肌的靶向治疗作用,现就此做一综述。
Abstract:
Exogenous exosomes (EXO) are extracellular vesicles produced by heart cells that contain a large number of biologically active molecules. They are important means of cardiac cell communication. In coronary heart disease, after special myocardial ischemia and hypoxia injury, special EXO components can be produced in 4 hours, which could be used as a new marker for early diagnosis. EXO secreted by stem cells such as cardiac progenitor cells can reduce myocardial cell apoptosis after coronary heart diseasecoronary heart diseasecoronary heart disease, increase cell tube formation, reduce the development of fibrosis, and improve cardiac function. These EXOs could be loaded with drugs that have therapeutic effects on the disease, labeled with myocardial targeting peptides, and exert a targeted therapeutic effect on ischemic myocardium. This article reviewed these

参考文献/References:


[1] Li J, Xue H, Li T, et al. Exosomes?derived from mesenchymal stem cells attenuate the progression of atherosclerosis in ApoE-/-?mice via miR-let7 mediated infiltration and polarization of M2 macrophage[J]. Biochem Biophys Res Commun,2019,510(4):565-572.

[2] Jin H, Wang H, Li J, et al. Differential contribution of the two waves of?cardiac?progenitors and their derivatives to aorta and pulmonary artery[J]. Dev Biol,2019, S0012-1606(18) :30807-30818.

[3] Vizoso FJ, Eiro N, Cid S, et al. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine[J].?Int J Mol Sci,2017,18(9):1852-1864.

[4] Tian C, Gao L, Zimmerman MC, et al. Myocardial infarction-induced microRNA-enriched exosomes contribute to cardiac Nrf2 dysregulation in chronic heart failure[J].?Am J Physiol Heart Circ Physiol,2018,314(5):928 -939.

[5] Yang Y, Li Y, Chen X, et al. Exosomal transfer of miR-30a between cardiomyocytes regulates autophagy after hypoxia[J].?J Mol Med,2016,94(6):711-724.

[6] Nie X, Fan J, Li H, et al. MiR-217 promotes cardiac hypertrophy and dysfunction by targeting PTEN[J].?Mol Ther Nucleic Acids,?2018,12(9):254-266.

[7] Cosme J, Guo H, Hadipour-Lakmehsari S, et al . Hypoxia-induced changes in the fibroblast s ecretome, exosome, and whole-cell proteome using cultured, cardiac-derived cells isolated from neonatal mice[J].?J Proteome Res, 2017,16(8):2836-2847.

[8] 徐佳,孙林.冠状动脉慢血流现象的风险标志物及预测因子的研究进展[J].心血管病学进展,2019,40(2):238-242.

[9] Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: Current perspectives and future challenges[J].?Acta Pharm Sin B,2016,6(4):287-296.

[10] Tang YT, Huang YY, Zheng L, et al. Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum[J].?Int J Mol Med,?2017,40(3):834-844.

[11] Barile L, Cervio E, Lionetti V, et al. Cardioprotection by cardiac progenitor cell-secreted?exosomes: role of pregnancy-associated plasma protein-A[J]. Cardiovasc Res, 2018,114(7):992-1005.

[12] Wu W, Li X, Zuo G, et al. The role of angiogenesis incoronaryarterydisease:a double-edged sword: intraplaque angiogenesis in physiopathology and therapeutic angiogenesis for treatment[J]. Curr Pharm Des,2018,24(4):451-464.

[13] Barani B, Rajasingh S, Rajasingh J. Exosomes:outlook for future cell-free cardiovasculardiseasetherapy[J].Adv Exp Med Biol,2017,998(6):285-307.

[14] Chang TY, Tsai WC, Huang TS, et al.Dysregulation of endothelial colony-forming cell function by a negative feedback loop of circulating miR-146a and -146b in cardiovascular?disease?patients[J]. PLoS One, 2017 ,12(7):e0181562.

[15] Boulanger CM, Loyer X, Rautou PE, et al. Extracellular vesicles in?coronary?artery?disease[J].Nat Rev Cardiol, 2017,14(5):259-272.

[16] Barile L, Cervio E, Lionetti V, et al. Cardioprotection by cardiac progenitor cell-secreted exosomes: Role of pregnancy-associated plasma protein-A[J].?Cardiovasc Res,2018,114(7): 992-1005.

[17] Nie S, Wang X, Sivakumaran P, et al. Biologically active constituents of the secretome of human W8B2+ cardiac stem cells[J].?Sci Rep,2018,8(1):1579.

[18] Cheow ES, Cheng WC, Lee CN,et al. Plasma-derived extracellular vesicles contain predictive biomarkers and potential therapeutic targets for myocardial ischemic (MI) injury[J].?Mol Cell Proteomics,2016,15(8):2628-2640.

[19] Cambria E, Pasqualini FS, Wolint P, et al. Translational cardiac stem cell therapy: Advancing from first-generation to next-generation cell types[J].?NPJ Regen Med,2017, 2(6):17-26.

[20] Middleton RC, Rogers RG, de Couto G, et al. Newt cells secrete extracellular vesicles with therapeutic bioactivity in mammalian cardiomyocytes[J].?J Extracell Vesicles,2018,7(1): 1456888.

[21] Kim MS, Haney MJ, Zhao Y, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells[J].?Nanomedicine,2016,12(3):655-664.

[22] Gallet R, Dawkins J, Valle J, et al. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction[J].?Eur Heart J,2017,38(3):201-211.

[23] Vandergriff A, Huang K, Shen D, et al. Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide[J].?Theranostics,?2018,8(7):1869-1878.

[24] Kim H, Yun N, Mun D, et al. Cardiac-specific delivery by cardiac tissue-targeting peptide-expressing exosomes[J].?Biochem Biophys Res Commun,2018,499(4):803-808.

[25] Wang X, Chen Y, Zhao Z, et al. Engineered exosomes with ischemic myocardium-targeting peptide for targeted therapy in myocardial infarction[J].?J Am Heart Assoc,2018,7(15):e008737-e008753.

相似文献/References:

[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
 DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(6):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
 NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]宋菲,综述,俞梦越,等.干细胞来源的外泌体:心肌梗死治疗新启示[J].心血管病学进展,2016,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.007]
 SONG Fei,YU Mengyue.Exosomes Derived from Stem Cells: Novel Approach in Treatment of Myocardial Infarction[J].Advances in Cardiovascular Diseases,2016,(6):125.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.007]
[4]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
 LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(6):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[5]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
 YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(6):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[6]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
 SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(6):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[7]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
 GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(6):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[8]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
 DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(6):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[9]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
 CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
 GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(6):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金面上项目( 31571168 , 30870908,81571246) 国家公派留学基金 20173059 收稿日期:2019-04-04
通讯作者: 陈艾东 E-mail: aidongchen @ njmu.edu.cn
更新日期/Last Update: 2019-12-09